TrialBlood advances2024

Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.

Andrew Spencer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.